BioSante Pharmaceuticals

About:

BioSante Pharmaceuticals is focused on developing products for female sexual health, menopause, contraception and male hypogonadism.

Website: http://www.biosantepharma.com

Top Investors: Great Point Partners, Deerfield Capital Management

Description:

BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.

Total Funding Amount:

$18M

Headquarters Location:

Lincolnshire, Illinois, United States

Founded Date:

1996-01-01

Contact Email:

pdonenberg(AT)biosantepharma.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2010-03-04

IPO Status:

Delisted

Industries:

© 2025 bioDAO.ai